by Leanne Talbot | Jul 26, 2019
NETs for Newcomers 2019 is now open for registration. This one-day course is for trainee doctors and consultants in all disciplines wishing to gain confidence in the diagnosis, investigation and management of patients with neuroendocrine tumours (NETs), including... by Leanne Talbot | Jul 23, 2019
At the 2019 meeting of the American Cancer Society of Clinical Oncologists (ASCO), Emily Bergsland, MD, University of California, San Francisco, reported on the results of a phase II clinical trial of pazopanib (PZ). The study evaluated how well PZ treats... by Leanne Talbot | Jul 23, 2019
Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 66th Annual... by Leanne Talbot | Jul 23, 2019
With nearly half of new diagnoses, and over half of cancer deaths being from rare or less common cancers, improving care and support for people with rare and less common cancers cannot be ignored. In 2018 over 670 people with a rare or less common cancer shared their... by Leanne Talbot | Jul 23, 2019
On the 22nd May, Cancer52 and PHE/NCRAS held an event focussed on the Developments in Data for Rare and Less Common Cancers. Tracey Genus presented NPF and PHE’s dataset for Neuroendocrine Cancers at the event. Lucy Elliss-Brookes, Head of Cancer Analysis at... by Leanne Talbot | Jul 23, 2019
For Eileen O’Sullivan, being diagnosed with breast cancer in 2013 was the catalyst for a deluge of distinctly unscientific and frequently dangerous advice. An investment manager with a analytical mind, she began seeking information to better understand her potentially... 